LIGAND PHARMACEUTICALS INCORPORATED Net Change in Cash
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Net Change in Cash of $831.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$59.83M.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$24.32M, a 189.61% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $27.14M, a 37.93% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $43.72M.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $102.62M, a 107.93% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $49.35M.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$22.05M, a 186.53% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $25.48M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $831.77M 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | -$59.83M 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $102.62M 10-K · filed 2026-02-27 | |||
| 2025-06-30 | -$4.64M 10-Q · filed 2026-08-07 | |||
| 2025-03-31 | -$24.32M 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | $49.35M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $40.66M 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | -$4.82M 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $27.14M 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | -$22.05M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | -$25.15M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$16.56M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $43.72M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $25.48M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | -$15.41M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$14.24M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$4.53M 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | -$24.53M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$25.96M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$15.77M 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | $384.83M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $43.61M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | $45.98M 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $106.53M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $154.62M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | -$12.41M 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $138.59M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $130.84M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $30.40M 10-Q · filed 2019-05-09 | |||
| 2017-09-30 | $13.99M 10-Q · filed 2018-11-08 |